Harriet de Wit, PhD, is a Professor in the Department of Psychiatry and Behavioral Neuroscience at the University of Chicago. She conducts research on the behavioral and neurobiological effects psychoactive drugs in healthy human volunteers. She has studied a range of drugs including alcohol, nicotine, stimulants, cannabis and, most recently, MDMA and LSD. Her studies aim to understand why people use drugs, and how drugs affect behavior. Her research has been funded by the National Institutes of Health for the past 40 years. She has trained numerous graduate students, post-doctoral fellows and undergraduates, and published over 300 papers. She serves on editorial boards of several scientific journals, and in 2019 received the Distinguished Achievement Award of the European Behavioural Pharmacology Society.
Psychedelics are a sui generis class of drugs whose effects and best practices were not anticipated by typical regulatory assumptions and trial designs. What lessons have scientists learned from decades of research and data, and how will the next generation of trials and studies offer more robust findings and valuable data? Join us to consider how researchers are innovating and moving the field forward.
